Prosthetic Heart Valve Market, Company Analysis and Forecast to 2024

Prosthetic Heart Valve Market Overview

Prosthetic (artificial) heart valve refers to a device implanted in the heart of a patient suffering from valvular heart disease. A cardiac surgery is performed to replace the abnormal heart valve with a prosthetic heart valve. Replacement of a diseased valve with a prosthetic heart valve results in reduction in morbidity and mortality associated with the cardiac valve disorder. When the treatment of heart valve disease reaches a stage where it does not provide relief to the patient, then surgery recommended as the best alternative to repair or replace the valve. In case of a valve replacement surgery, carbon based mechanical valves and biological tissue valve are the types of valves that can be selected based on the condition. Advancements in technology and increasing prevalence of heart valve diseases are some major factors projected to drive growth of the prosthetic heart valve market in the near future.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/69

Selection of a Heart Valve also depends on the Type of Polymer

On the basis of product type, the global prosthetic heart valve market can be segmented into mechanical heart valves, transcatheter heart valves, and tissue heart valves. Tissue heart valves are harvested from pig heart valves and cow heart sac. The life of a tissue valve is 10 to 15 years. Tissue heart valves is further classified into stented tissue valve, stentless tissue valve, tissue-engineered valves, homograft valves, and heterograft valves. Aortic valves and mechanical mitral valves are the two types of mechanical heart valves.

Technologies for prosthetic heart valves include anti-calcification, sutureless valves, polymers, and carbon-based technologies. The primary cause of failure of bioprosthetic valves is structural valve deterioration due to tissue calcification. An anticalcification technology was developed that may irreversibly choke calcium binding sites in bioprosthetic valves. In February 2016, the U.S. FDA approved a new technology called sutureless aortic valve replacement that is used for treatment of aortic valve disease. Sutureless valves are used to treat aortic valve disease and is a relatively less invasive for patients. The use of polymers to produce leaflet valves, which have same benefit of bioprosthetic and mechanical valves has been available since mid-1950s. Much attention has been focused on thermoplastic polyurethanes due to its various beneficial properties.

Developed Nations Current Hubs, while Low and Middle Income Countries to emerge as Major Markets

Increasing prevalence of heart diseases, technological advancements, government funding, robust healthcare infrastructure, and rise in healthcare expenditure in the U.S. are major factors projected to propel growth of the prosthetic heart valve market in this region. According to Centers for Diseases Control and Prevention (CDC) about 610,000 people die due to heart diseases in U.S. every year. The growth of prosthetic heart valve market in Asia is expected to be high in the near future due to increasing incidence of various chronic diseases and improving healthcare infrastructure in this region. According to a study published in the Lancet—a U.K.-based medical journal—the number of people affected by high blood pressure has almost doubled over past 40 years (from 1975 to 2015).

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/ongoing-insight/prosthetic-heart-valve-market-69

Growing Aging Population highly susceptible to Heart Diseases to Spur growth of the prosthetic heart valve market

Advancements in technology, increasing aging population, and significant rise in prevalence of heart valve disorder are some factors that are expected to drive growth of the prosthetic heart valve market in the near future. However, factors such as high costs of development, stringent government regulations, reimbursement issues, and lack of trained professionals are inhibiting growth of the prosthetic heart valve market to certain extent.

Global players involved in the prosthetic heart valve market

The prosthetic heart valve market is characterized by the presence of major global players. Some of the prominent names include Boston Scientific Corporation, St. Jude Medical, Inc., Sorin S.P.A, Abbott Laboratories, Claret Medical, Inc., AorTech, Edwards Lifesciences Corporation, Neovasc Inc., and JenaValve Technology.

Better Patient Outcomes utilizing Prosthetic Heart Valves to Ensure Sustained Demand

Developed regions such as North America and Europe are rapidly growing regions in the prosthetic heart valve market, mainly attributed to robust healthcare infrastructure, increasing prevalence of valvular heart disease, and favorable reimbursement scenario. The experience of using an aortic bioprosthetic valve treated with anticalcification tissue technology demonstrates excellent valve performance, safety, and durability. Minimally invasive devices for treatment of heart surgery are the need of the hour to ensure better patient experience. The sutureless valve technology is less invasive for patients, which is expected to witness higher adoption in the near future. Transcatheter has given improved patient survival rate when compared with medical therapy.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.